Autoantibodies and microvascular damage are independent predictive factors for the progression of Raynaud's phenomenon to systemic sclerosis: A twenty‐year prospective study of 586 patients, with validation of proposed criteria for early systemic sclerosis

Wiley - Tập 58 Số 12 - Trang 3902-3912 - 2008
Martial Koenig1, France Joyal, Marvin J. Fritzler2, André Roussin3, Michał Abrahamowicz4, Gilles Boire5, Jean‐Richard Goulet3, Éric Rich3, Tamara Grodzicky3, Yves Raymond3, Jean‐Luc Senécal6
1Notre-Dame Hospital, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada
2University of Calgary, calgary, Alberta, canada
3Notre-Dame Hospital, Centre Hospitalier de l'Université de Montréal, and Université de Montréal, Montreal, Quebec, Canada
4McGill University, Montreal, Quebec, Canada
5Centre Hospitalier Universitaire de Sherbrooke and Université de Sherbrooke; Sherbrooke Quebec Canada
6Notre‐Dame Hospital, Centre Hospitalier de l'Université de Montréal, and Université de Montréal, Montreal, Quebec, Canada

Tóm tắt

AbstractObjective

To identify in patients with Raynaud's phenomenon (RP) independent markers that predict progression to definite systemic sclerosis (SSc) and to determine in patients with progression to SSc the type and sequence of microvascular damage and its relationship to SSc‐specific autoantibodies.

Methods

Consecutive patients referred for evaluation of RP who had no definite connective tissue disease were evaluated for microvascular damage by nailfold capillary microscopy (NCM) and for anticentromere (anti–CENP‐B), anti‐Th/To, anti–topoisomerase I, and anti–RNA polymerase III (anti–RNAP III) autoantibodies by specific assays. Patients were studied prospectively.

Results

Of the 586 patients who were followed up for 3,197 person‐years, 74 (12.6%) developed definite SSc. A characteristic sequence of microvascular damage was identified, starting with enlarged capillaries, followed by capillary loss, and then by capillary telangiectases. Definite SSc was diagnosed in close temporal relationship to capillary loss. Enlarged capillaries, capillary loss, and SSc‐specific autoantibodies independently predicted definite SSc. Anti–CENP‐B and anti‐Th/To antibodies predicted enlarged capillaries; these autoantibodies and anti–RNAP III predicted capillary loss. Each autoantibody was associated with a distinct time course of microvascular damage. At followup, 79.5% of patients with 1 of these autoantibodies and abnormal findings on NCM at baseline had developed definite SSc. Patients with both baseline predictors were 60 times more likely to develop definite SSc. The data validated the proposed criteria for early SSc.

Conclusion

In RP evolving to definite SSc, microvascular damage is dynamic and sequential, while SSc‐specific autoantibodies are associated with the course and type of capillary abnormalities. Abnormal findings on NCM at baseline together with an SSc‐specific autoantibody indicate a very high probability of developing definite SSc, whereas their absence rules out this outcome.

Từ khóa


Tài liệu tham khảo

10.1172/JCI31139

10.7326/0003-4819-140-1-200401060-00010

Maricq HR, 1983, Microvascular abnormalities as possible predictors of disease subsets in Raynaud phenomenon and early connective tissue disease, Clin Exp Rheumatol, 1, 195

10.1093/rheumatology/kel295

10.1016/0002-9343(80)90462-3

10.1016/0002-9343(82)90846-4

10.1002/art.1780280114

Houtman PM, 1986, Diagnostic significance of nailfold capillary patterns in patients with Raynaud's phenomenon: an analysis of patterns discriminating patients with and without connective tissue disease, J Rheumatol, 13, 556

10.1016/0002-9343(87)90760-1

10.1136/ard.47.8.634

10.1016/0002-9343(88)90109-X

10.1111/j.1365-2362.1989.tb00271.x

Gentric A, 1990, Serological arguments for classifying Raynaud's phenomenon as idiopathic, J Rheumatol, 17, 1177

10.1002/art.1780340111

10.1007/BF02283115

10.1016/0049-0172(94)90098-1

10.1016/0190-9622(95)91453-6

Luggen M, 1995, The evolution of Raynaud's phenomenon: a longterm prospective study, J Rheumatol, 22, 2226

10.1016/S0741-5214(05)80037-0

Hirschl M, 1996, Initial prevalence and incidence of secondary Raynaud's phenomenon in patients with Raynaud's symptomatology, J Rheumatol, 23, 302

LeRoy EC, 2001, Criteria for the classification of early systemic sclerosis, J Rheumatol, 28, 1573

10.1002/art.21912

Maricq HR, 1977, Studies in patients with connective tissue disorders, Bibl Anat, 16, 135

10.1002/art.1780240907

10.1002/1529-0131(200103)44:3<735::AID-ANR125>3.0.CO;2-F

Senecal JL, 2005, The pathogenic role of autoantibodies to nuclear autoantigens in systemic sclerosis, J Rheumatol, 32, 1643

Raynaud M, 1862, Thèse de Médicine: De l'asphyxie locale et de la gangrène des extremités

10.1056/NEJMcp013013

10.1097/00005792-200203000-00005

Clements P, 1995, Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis, J Rheumatol, 22, 1281

10.1016/0026-2862(86)90062-2

10.1002/art.1780310309

10.1002/art.1780370214

10.1002/art.11173

10.1186/ar2276

10.1191/0961203306lu2327oa

10.1002/art.20515

10.1002/art.21232

Venables PJ, 2003, Rheumatology, 1523

10.1002/art.1780230510

Giordano M, 1986, Different antibody patterns and different prognoses in patients with scleroderma with various extent of skin sclerosis, J Rheumatol, 13, 911

10.1002/1529-0131(200002)43:2<444::AID-ANR27>3.0.CO;2-G

10.1001/archinte.158.6.595

10.1002/art.22636

10.1002/art.20676

10.1002/art.22314

10.1016/0002-9343(84)90517-5

10.1093/rheumatology/keh156

Ihata A, 2000, Severity of seropositive isolated Raynaud's phenomenon is associated with serological profile, J Rheumatol, 27, 1686